Enhancements of screening collections to address areas of unmet medical need: an industry perspective.
The past 20 years have witnessed an impressive expansion of the 'drug space'; defined as the intersection of the Medicinal Chemistry space and the Biologically Active space relevant in the quest for new treatments for disease. Despite the success of known lead discovery tactics, areas of unmet medical need are often linked to challenging or novel targets and are poorly served by current screening collections. A successful strategy to fill the gaps is to diversify the approaches taken in the enhancement of screening collections. Possible strategies include investments through proven methods, exploring areas of chemical space previously neglected (e.g. hydrophilic compounds, natural product mimics), and applying tactics to the lead discovery process that are complementary to HTS (e.g. fragment based screening or multidisciplinary team efforts to tackle new target classes).
Drewry
David H
DH
Molecular Discovery Research, GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA. david.h.drewry@gsk.com
Macarron
Ricardo
R
D055808:Drug Discovery / Q000379:methods*; D004345:Drug Industry; D057166:High-Throughput Screening Assays / Q000379:methods; D006801:Humans; D054852:Small Molecule Libraries
D054852:Small Molecule Libraries